Chikungunya Virus – An Emerging Threat to the Americas

Clinician Outreach and Communication Activity (COCA) Conference Call
February 18, 2014
Objectives

At the conclusion of this session, the participant will be able to accomplish the following:

- Describe which patients to test for the infection
- Explain testing, treatment and prevention measures for chikungunya
- Understand the importance of early recognition and reporting of cases
Continuing Education Disclaimer

In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC does not accept commercial support.
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 1.0 contact hours.

IACET CEU: The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer 0.1 ANSI/IACET CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number GA0082.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-13-146-H04-P. This program is knowledge based.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.2 hours of continuing education in jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
TODAY’S PRESENTER

J. Erin Staples, MD, PhD
Medical Epidemiologist
Arboviral Diseases Branch
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Chikungunya virus disease

- Mosquito-borne viral disease characterized by acute onset of fever and severe polyarthralgia
- Often occurs in large outbreaks with high attack rates
- Outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans
- In 2013, first locally-acquired cases in the Americas reported on islands in the Caribbean
Countries with reported local transmission of chikungunya virus*

*As of February 10, 2014
Seven Caribbean countries have reported locally-acquired cases

>1,000 laboratory-confirmed cases have been reported

Virus expected to spread to new areas

*As of February 10, 2014*
Chikungunya virus in the United States

- Chikungunya virus is not currently found in U.S.
- From 2006-2009, 106 laboratory-confirmed chikungunya cases identified in travelers visiting or returning to U.S.
  - None triggered a local outbreak in U.S.
- With outbreaks in Caribbean, number of chikungunya cases among U.S. travelers will likely increase
- Imported cases may result in virus introduction and local spread in some areas of U.S.
Chikungunya virus

- Single-stranded RNA virus
- Genus *Alphavirus*
- Family *Togaviridae*
- Closely related to Mayaro, O’nyong-nyong, and Ross River viruses
Mosquito vectors

- Predominantly *Aedes aegypti* and *Aedes albopictus*
- Same mosquitoes that transmit dengue
- Widely distributed throughout Americas
- Aggressive daytime biters

*Aedes aegypti*    *Aedes albopictus*
Primary transmission cycle

Anthroponotic transmission
(person to mosquito to person)
Other modes of transmission

- Documented rarely
  - *In utero* transmission resulting in abortion
  - Intrapartum from viremic mother to child
  - Percutaneous needle stick
  - Laboratory exposure

- Theoretical concern
  - Blood transfusion
  - Organ or tissue transplantation

- No evidence of virus in breast milk
Chikungunya virus infection

- Majority (72%–97%) of infected people develop clinical symptoms
- Incubation period usually 3–7 days (range 1–12 days)
- Primary clinical symptoms are fever and polyarthralgia
Fever and polyarthralgia

- **Fever**
  - Abrupt onset
  - Typically ≥39.0°C (≥102.2°F)

- **Joint pain**
  - Often severe and debilitating
  - Involves multiple joints
  - Usually bilateral and symmetric
  - Most common in hands and feet
Other clinical signs and symptoms

- Headache
- Myalgia
- Arthritis
- Conjunctivitis
- Nausea/vomiting
- Maculopapular rash
Clinical laboratory findings

- Lymphopenia
- Thrombocytopenia
- Elevated creatinine
- Elevated hepatic transaminases
Atypical disease manifestations

- Uveitis
- Retinitis
- Hepatitis
- Nephritis
- Myocarditis
- Hemorrhage
- Myelitis
- Cranial nerve palsies
- Guillain-Barre syndrome
- Meningoencephalitis
- Bullous skin lesions*

*Primarily described in neonates
Risk factors for hospitalization or atypical disease

- Neonates exposed intrapartum
- Older age (e.g., >65 years)
- Underlying medical conditions (e.g., diabetes, hypertension, or cardiovascular disease)
Clinical outcomes

- Acute symptoms typically resolve in 7–10 days
- Mortality is rare; occurs mostly in older adults
- Some patients have relapse of rheumatologic symptoms* in the months following acute illness
- Studies report variable proportions of patients with persistent joint pains for months or years

*Polyarthralgia, polyarthritis, tenosynovitis, Raynaud’s syndrome
Diagnostic testing

- Culture for virus*
- Reverse transcriptase-polymerase chain reaction (RT-PCR) for viral RNA
- Serology for IgM and confirmatory neutralizing antibodies
- Serology for $\geq 4$-fold rise in virus-specific quantitative antibody titers on paired sera†

*Virus should be handled under biosafety level (BSL) 3 conditions
†Determined by plaque reduction neutralization test (PRNT) or immunofluorescence assay (IFA)
## Optimal timing for diagnostic assays

<table>
<thead>
<tr>
<th>Diagnostic assay</th>
<th>Days post-illness onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral culture</td>
<td>≤3 days</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>≤8 days</td>
</tr>
<tr>
<td>IgM antibody tests</td>
<td>≥4 days</td>
</tr>
</tbody>
</table>
Laboratories for diagnostic testing*

- Testing performed at:
  - CDC Arboviral Diseases Branch
  - Several state health departments†
  - One commercial laboratory (Focus Diagnostics)‡

- Contact your state health department for information or to facilitate testing

*As of February 2014
†California, Florida, and New York
‡Testing may be ordered through other commercial laboratories and will be forwarded to Focus Diagnostics for testing
Treatment

- No specific antiviral therapy
- Supportive care with rest and fluids
- Non-steroidal anti-inflammatory drugs (NSAIDs) for acute fever and pain*
- Persistent joint pain may benefit from use of NSAIDs, corticosteroids, or physiotherapy

*Aspirin use is discouraged due to a theoretical risk of hemorrhage or Reye syndrome
Distinguishing dengue from chikungunya

- Viruses transmitted by same mosquitoes
- Diseases have similar clinical features
- Viruses can circulate in same areas and cause co-infections
- Important to rule out dengue, as proper clinical management can improve outcome

## Clinical features of chikungunya virus infections compared with dengue virus infections

<table>
<thead>
<tr>
<th></th>
<th>Chikungunya</th>
<th>Dengue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever (&gt;39°C)</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>+++</td>
<td>+/-</td>
</tr>
<tr>
<td>Arthritis</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Headache</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Rash</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Myalgia</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>+/-</td>
<td>++</td>
</tr>
<tr>
<td>Shock</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>
Laboratory features of chikungunya virus infections compared with dengue virus infections

<table>
<thead>
<tr>
<th></th>
<th>Chikungunya</th>
<th>Dengue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphopenia</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>Hemoconcentration</td>
<td>-</td>
<td>++</td>
</tr>
</tbody>
</table>
Differential diagnosis for chikungunya

- Dengue
- Leptospirosis
- Malaria
- Rickettsia
- Parvovirus
- Enterovirus
- Group A streptococcus
- Rubella
- Measles
- Adenovirus
- Post-infectious arthritis
- Rheumatologic conditions
- Other alphavirus infections (e.g., Mayaro, Ross River, Barmah Forest, O’nyong-nyong, and Sindbis viruses)
Surveillance

- Inform travelers going to areas with known virus transmission about risk of disease
- Consider chikungunya in patients with acute onset of fever and polyarthralgia
- Be aware of possible local transmission in areas where *Aedes* species mosquitoes are active
Reporting of chikungunya cases

- Suspected cases should be reported to state or local health departments to
  - Facilitate diagnosis
  - Mitigate risk of local transmission

- State health departments encouraged to report laboratory-confirmed cases to CDC
Preventive measures

- No vaccine or medication available to prevent infection or disease
- Primary prevention measure is to reduce mosquito exposure
- Advise persons at risk for severe disease to avoid travel to areas with ongoing outbreaks
- Protect infected people from further mosquito exposure during first week of illness
Mosquito prevention and control

- Use air conditioning or window/door screens
- Use mosquito repellents on exposed skin
- Wear long-sleeved shirts and long pants
- Empty standing water from outdoor containers
- Support local vector control programs
Selected references

Additional resources

- General information about chikungunya virus and disease:  
  http://www.cdc.gov/chikungunya/

- Protection against mosquitoes:  

- Travel notices:  http://wwwnc.cdc.gov/travel/notices

- Information for travelers and travel health providers:  

- Chikungunya preparedness and response guidelines:  
Questions

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
To Ask a Question

- **Using the Webinar System**
  - “Click” the Q&A tab at the top left of the webinar tool bar
  - “Click” in the white space
  - “Type” your question
  - “Click” ask

- **On the Phone**
  - Press Star (*) 1 to enter in the queue to ask a question
  - State your name
  - Listen for the operator to call your name
  - State your organization and then ask your question
Centers for Disease Control and Prevention
Atlanta, Georgia
Accrediting Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 1.0 contact hours.

IACET CEU: The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer 0.1 ANSI/IACET CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number GA0082.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-13-146-H04-P. This program is knowledge based.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.2 hours of continuing education in jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
Continuing Education guidelines require that the attendance of all who participate in COCA Conference Calls be properly documented. All Continuing Education credits/contact hours (CME, CNE, CEU, CECH, ACPE and AAVSB/RACE) for COCA Conference Calls/Webinars are issued online through the CDC Training & Continuing Education Online system [http://www.cdc.gov/TCEOnline/](http://www.cdc.gov/TCEOnline/).

Those who participate in the COCA Conference Calls and who wish to receive CE credit/contact hours and will complete the online evaluation by **March 19, 2014** will use the course code **WC2286(SC)**. Those who wish to receive CE credits/contact hours and will complete the online evaluation between **March 20, 2014** and **February 17, 2015** will use course code **WD2286(SC)**. CE certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained through the CDC Training & Continuing Education Online System will be maintained for each user.
Thank you for joining!
Please email us questions at coca@cdc.gov

http://emergency.cdc.gov/coca
Join Us on Facebook

CDC Facebook page for Health Partners! “Like” our page today to receive COCA updates, guidance, and situational awareness about preparing for and responding to public health emergencies.

http://www.facebook.com/CDCHealthPartnersOutreach